SCHEMBL2179355

SCHEMBL2179355

CCCCOc1ccc(C(=O)Nc2ccc(-c3ccc4c(c3)C(=O)N(C(C(=O)O)C(C)C)C4)cc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.48
MCHR1 Q99705 2/20 0.48
HPGD P15428 1/20 0.48
TSHR P16473 1/20 0.48
TAAR1 Q96RJ0 1/20 0.48
HSD17B10 Q99714 1/20 0.48
LMNA P02545 3/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
KDM4E B2RXH2 2/20 0.47
TP53 P04637 2/20 0.47
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
STAT3 P40763 1/20 0.45
ALDH1A1 P00352 1/20 0.44
HIF1A Q16665 1/20 0.44
RAB9A P51151 1/20 0.44
NR1H4 Q96RI1 2/20 0.44
NPC1 O15118 1/20 0.44
ITGB3 P05106 1/20 0.43
ITGA2B P08514 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13719368 1.00 MAPT (0.48) MAPTMCHR1HPGDTSHRTAAR1
SCHEMBL2180319 0.92 MAPT (0.47) MAPTMCHR1HPGDTSHRTAAR1
SCHEMBL2177947 0.91 MEN1 (0.47) MAPTMCHR1HPGDTSHRTAAR1
SCHEMBL2181553 0.91 MEN1 (0.47) MAPTMCHR1HPGDTSHRTAAR1
SCHEMBL2177126 0.90 MEN1 (0.47) MAPTMCHR1HPGDTSHRTAAR1
SCHEMBL2179919 0.90 MEN1 (0.43) MAPTMCHR1HPGDTSHRTAAR1
SCHEMBL2180778 0.90 MEN1 (0.47) MAPTMCHR1HPGDTSHRTAAR1
SCHEMBL2180348 0.90 MEN1 (0.47) MAPTMCHR1HPGDTSHRTAAR1
SCHEMBL13719175 0.90 MEN1 (0.43) MAPTMCHR1HPGDTSHRTAAR1
SCHEMBL2179853 0.90 MEN1 (0.47) MAPTMCHR1HPGDTSHRTAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US claimed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US claimed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP claimed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO claimed
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US disclosed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US disclosed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP disclosed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE DGAT1, DGAT2, LCAT MAPT 116/4885MCHR1 4705/4885HPGD 1252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.